th PVRI Annual World Congress - pvrinstitute.org · pathway medications on hospitalization among patients with PH: a retrospective administrative claims study in a US managed care

January // Barcelona 2019

Abstract Presentations Programme

13th PVRI Annual World Congresson Pulmonary Vascular Disease

Pulmonary Vascular Research Institute

PVRI

10:30-12:30 Held in // Verdi Room

Best Abstract Oral Presentations (four basic & four clinical)10 minute presentations with 5 minute q&aModerators: • Vinicio de Jesus Perez • Kimio Satoh • Gérald Simonneau • Geoff Strange

• anna Hemnes • Sébastien Bonnet

abstract Title: Presenter: abstract Category

Wnt-signalling pathway drives right Sreenath Nayakanti 28 Basicventricular remodelling.

Frataxin deficiency induces endothelial Miranda Culley 37 Basicreplication stress, DNa damage response, and senescence to promote pulmonary hypertension.

17ß-estradiol (E2) and estrogen receptor Andrea Frump 105 Basic∂(ER∂) modulate BMPR2 and apelin to promote protective effects on right ventricular function in pulmonary hypertension.

BRD4 antagonist RVX208 reverses vascular Konda Babu Kurakula 137 Basicremodeling and supports the right ventricle in pulmonary arterial hypertension via PLK1 and FoxM1.

Cross-altitude analysis suggests a turning Chaoying Cui 2 Clinicalpoint at the elevation of 4,500m for polycythemia prevalence in Tibetans.

Prescription amphetamine-based substances and the risk of pulmonary arterial Ramon Ramirez 18 Clinicalhypertension.

ESC/ERS low-risk profile achievement Valentina Mercurio 35 Clinicalaccurately predicts mortality in scleroderma-associated PaH.

Initial combination therapy with riociguat Jason Weatherald 165 Clinicaland ambrisentan in pulmonary arterial hypertension: interim analysis from a prospective open-label study.

Thursday 31 January


Late-Breaking Oral Clinical Abstract Presentations10 minute presentations with 2 minute q&aModerators: • Paul Hassoun • Paul Corris


Ralinepag plasma levels correlate with Harrison Farber 8 Clinicalimprovements in functional and hemodynamic parameters in patients with pulmonary arterial hypertension.

Sorafenib in hepatopulmonary syndrome Steven Kawut 21 Clinical(SHPS): a randomized, double-blind placebo-controlled trial.

Characteristics of patients with CTD- Kristin Highland 75 Clinicalassociated PaH treated with selexipag in the real-world setting: Interim data fromthe SPHERE registry.

Treatment with oral treprostinil is Jim White 132 Clinicalassociated with improved survival in pulmonary arterial hypertension participants from the FREEDOM-EV Study.

2 3

Friday 1 February

4 5


Rapid Fire Oral Presentation Session for Basic Science3 minute presentations with 2 minute q&aModerators: • Stephen archer • Soni Savai-Pullamsetti


Lung single-cell transcriptomics of two Jason Hong 57 Basicanimal models of pulmonary arterial hypertension reveals vulnerable cell types and pathways.

a genome-wide association study to identify Adel El Boueiz 93 Basicgenetic determinants of pulmonary vascular remodelling in COPD.

When the clock stop ticking: The role Roxane Paulin 119 Basiccircadian clock core protein Rev-Erb∂ in pulmonary arterial hypertension.

Endothelial-derived endothelin-1 inhibits Anggoro Budi Hartopo 152 Basiclymphangiogenesis and promotes fibrosis in mice model of pulmonary fibrosis.

a role for bone morphogenetic protein Alex Crosby 154 Basictype 2 receptor in the differentiation of the myeloid lineage in humans and mice.


Rapid Fire Oral Presentation Session for Clinical Science3 minute presentations with 2 minute q&aModerators: • Joan albert Barbera • Paul Williams • Redga Girgis


The bone morphogenetic protein (BMP10) Melanie Eyries 16 Clinicalgene widens the landscape of heritable pulmonary arterial hypertension mutations.

Biomarker behavior in children with Ernesto Juaneda 71 Clinicalpulmonary hypertension risk due congenital heart surgery: a single centre experience in argentine pediatric patients with oral citrulline suplementation.

artificial intelligence to separate and measure Pietro Nardelli 89 Clinicalarteries and veins in Non-Contrast CT.

Outcome of pulmonary thromboendar- Farid Rashidi 125 Clinicalterectomy in chronic thromboembolic disease with normal hemodynamic: is it time to change the definition of CTEPH.

DELTa-LIKE 4 inhibitor treatment causes Patricia Thistlethwaite 144 Clinicalpulmonary arterial hypertension in humans - review of 6 randomized clinical trials.

Saturday 2 February

18:15-19:30 Held in // Rossini, Terraza & Vivaldi Rooms

MODERATED CLINICAL POSTER SESSION

Clinical Treatments & Cohort in PAHModerators: • Olivier Sitbon • Patricia Thistlethwaite


Clinical pharmacokinetic performance of a John Grundy 7 Clinicalralinepag extended-release tablet.

Pulmonary capillary surface area in supine David Langleben 19 Clinicalexercising humans: demonstration of vascular recruitment.

Investigation of frailty status in patients with Bahri Akdeniz 33 Clinicalpulmonary hypertension.

In-child experience of the selective prostacyclin Martin Koestenberger 34 Clinicalreceptor agonist selexipag in pediatric pulmonary hypertension.

Comparative effectiveness of oral prostacyclin Janis Pruett 40 Clinicalpathway medications on hospitalization among patients with PH: a retrospective administrative claims study in a US managed care population.

Favourable response to PaH specific therapies Zeki Ongen 41 Clinicalin pulmonary capillary hemangiomatosis.

Composite goals plus inflammation: further risk Junyan Qian 47 Clinicalassessment for SLE-PaH in CSTaR-PaH cohort.

Multiparameter risk assessment tools applied to Cassandra Lickert 66 Clinicalthe functional class (FCII) cohort from the EaRLY(aC-052364) clinical trial.

Importance of atrial fibrillation in patients with Bahri Akdeniz 70 Clinicalpulmonary arterial hypertension.

Effect of transitioning from phosphodiesterase Kelly Sun 73 Clinicaltype 5 inhibitors (PDE5i) to riociguat.

Interim analysis of pulmonary arterial Anna Hemnes 76 Clinicalhypertension (PaH)-targeted background therapy in SPHERE (SelexiPag: tHe usErs dRug rEgistry).

6 7


Subcutaneous treprostinil treatment experience Gulfer Okumus 86 Clinicalin pulmonary hypertension.

10 years bosentan therapy in a patient with Gulfer Okumus 87 Clinicaleisenmenger syndrome.

Feasibility of utilising one-day vs seven-day Robert Frantz 94 Clinicalresults of the pulmonary arterial hypertension (PaH)-SYMPaCT tool.

Open-label Phase 1 study to investigate drug Peter Fernandes 106 Clinical- drug interactions between pulsed, inhaled nitric oxide (INO) and Sildenafil in healthy volunteers.

Melatonin and Hemin treatment in neonatal Alejandro 116 Clinicalpulmonary hypertension improves molecular Gonzalez-Candiamarkers of vascular function.

Protocol and rationale for the Study of Mohamad Taha 138 Clinicalangiogenic cell therapy for ProgressivePulmonary Hypertension: Intervention with Repeat dosing of eNOS-enhanced EPCs (SaPPHIRE).

Use of aerosolized prostacyclins for right Syed Hussain 146 Clinicalventricular dysfunction in hypoxemic respiratory failure.

Syncope and outcomes in paediatric pulmonary Usha Krishnan 149 Clinicalhypertension.

Shall we close the aSD after PaH specific Umit Yasar Sinan 155 Clinicaltherapy?

Long-term benefits of intravenous epoprostenol Tegan Dunmall 162 Clinicalin idiopathic pulmonary arterial hypertension - a personal experience.

The benefit of right heart rechatheterization in Vera Dewanto 167 Clinicaldrug-treated pulmonary arterial hypertension patients.

Compliance is more than taking your pills Marc Pritzker 170 Clinicalon time.

Saturday 2 February ...continued

Secondary PHT (CTEPH/Altitude/Lung & Heart Failure)Moderators: • ardeschir Ghofrani • Isabel Blanco


Left heart, right heart, and ventricular-ventricular Martin Koestenberger 3 Clinicalinteraction variables in children with pulmonary hypertension.

Imatinib for recurrent right heart decompensation Horst Olschewski 11 Clinicalin COPD - a case report.

The ten year outcomes of CTEPH patients in a Mehmet Serdar Kucukoglu 14 Clinicaluniversity hospital.

Haemodynamic assessment is important in Hakki Simsek 20 Clinicalpatients with congenital heart anomalies.

Wedge pulmonary angiography prognostic value Carlos Sisniega 22 Clinicalbefore cardiac surgery in patients with congenital heart disease and pulmonary hypertension: a single centre experience.

Outcomes of pregnancy associated with Shine Kumar 23 Clinicalpulmonary arterial hypertension.

Pulmonary arterial hypertension and sepsis: Frantzeska Frantzeskaki 30 Clinicala two-edged sword.

Real life data of anticoagulant treatment use in Tarik Kivrak 64 Clinicalchronic thromboembolic pulmonary hypertension patients:a retrospective cohort study of center.

Severe pulmonary hypertension (PH) in children Gabriel Diaz 67 Clinicalbetween 1 and 5 years old living at altitude, in Bogota, located at 2,640 meters over sea level (mosl).

Left ventricle outflow tract obstruction in Olena Torbas 69 Clinicalpulmonary hypertension.

Baseline demographics and clinical Michele Cole 72 Clinicalcharacteristics of chronic thromboembolic pulmonary hypertension patients within medicare Medicare population.

8 9


The Europe, Middle East and africa (EMEa) Gul Ongen 78 Clinicalchronic thromboembolic pulmonary hypertension (CTEPH) registry: study design and baseline demographics.

Single center experience of pulmonary Farid Rashidi 80 Clinicalthromboendarterectomy for chronic thromboembolic pulmonary hypertension.

Proximal vs. distal end-stage CTEPH: Insights Dijana Iloska 90 Clinicalfrom histopathological and molecular perspective.

Pulmonary hypertension (PH) in patients with Elena Jureviciene 91 Clinicalchronic obstructive pulmonary disease (COPD): Lithuanian National Database analysis.

Borg dyspnea score adjusted six minute walk Youlan Rao 95 Clinicaldistance in pulmonary arterial hypertension clinical trials.

Chronic thromboembolic pulmonary Agueda Aurtenetxe 110 Clinicalhypertension. Observational study in referral unit.

Balloon pulmonary angiography and stenting of Derya Kocakaya 124 Clinicala familial pulmonary arterial tortuosity patient and reperfusion related pulmonary injury.

Determinants of longitudinal vascular pruning Raul San Jose Estepar 131 Clinicalin smokers.

Pulmonary trunk dissection in a schistosomiasis Angela Pontes Bandeira 140 Clinicalpatient: a case report.

a “Treat and repair” strategy for patients with Usha Krishnan 150 Clinicalcongenital systemic-pulmonary shunts and pulmonary vascular disease.

Cor pulmonale in multi-facet miner lung disease: Kemi Tibazarwa 153 Clinicalshould we lower the standard echo thresholds.

Rapid Riociguat titration in pulmonary arterial Zeenat Safdar 158 Clinicalhypertension and chronic thromboembolic pulmonary hypertension patients.



Peri-operative right heart echocardiography Rajarajan Ganesan 163 Clinicalchanges in pulmonary hypertension associated with congenital heart disease.

Balloon pulmonary angioplasty to treat chronic Angela Pontes Bandeira 169 Clinicalthromboembolic pulmonary hypertension: an initial experience in a tertiary medical center in Pernambuco-Brazil.

Registries DataModerator: • Raymond Benza


Study on constituent ratio and trend of severe Hua Luo 9 Clinicalpulmonary vascular diseases inpatients from 2002 to 2015 in Chinese comprehensive hospital.

analysis of pulmonary hypertension patient Yuriy Sirenko 12 Clinicalsurvival after treatment in specialised unit (data of first Ukrainian register).

Pulmonary hypertension patient survival in Yuriy Sirenko 13 Clinicaldifferent etiology subgroups after treatment in specialised unit (data of first Ukrainian register).

The increasing prevalence of pre-capillary PH Umit Yasar Sinan 15 Clinicalaccording to new PH definition described on 6th WSPH Congress.

The Jogjakarta COngenital HeaRt Disease and Anggoro Budi Hartopo 151 ClinicalPulmonary Hypertension (COHaRD-PH) registry: a single-center hospital-based registry of adult ongenital heart disease and pulmonary artery hypertension in Indonesia.

Preliminary results of a national registry of Lucilla Piccari 168 Clinicalpulmonary hypertension associated with respiratory diseases.

10 11

ImagingModerator: • Evan Brittain


advanced interstitial lung fibrosis with Horst Olschewski 10 Clinicalemphysema and pulmonary hypertension with no evidence for interstitial lung disease in thin slice CT.

Diffuse microvascular ischemia after lung Kevin Tsui 25 Clinicaltransplantation in a patient with pulmonary arterial hypertension.

Increased mortality associated with borderline Geoff Strange 36 Clinicalpulmonary hypertension: Insights from The National Echocardiography Database of australia.

The prevalence and prognosis of pulmonary Matshela Mamotabo 117 Clinicalhypertension in patients with systolic heart Rossyfailure: Echocardiography based sub-study, HaFRES registry.

The prognostic implications pulmonary Matshela Mamotabo 118 Clinicalhypertension in pregnancy: echocardiography Rossybased study.

CT changes in proximal and distal pulmonary Nick Rahaghi 143 Clinicalvasculature in exercise pulmonary arterial hypertension.


Held in // Rossini, Terraza & Vivaldi RoomsMODERATED BASIC POSTER SESSION

RV Failure & Epigenetic in PAHModerators: • Tim Lahm • Harm-Jan Bogaard


Early RV-Pa uncoupling is associated with a Bradley Wertheim 1 Basicdistinct pulmonary endothelial transcriptomic phenotype in experimental pulmonary arterial hypertension in vivo.

MicroRNa96 delivered direct to the lungs Mandy MacLean 6 Basicreverses Sugen/hypoxia-induced pulmonary hypertension in the rat.

Blood-borne microRNa-210 promotes Jingsi Zhao 39 Basicpulmonary hypertension via extracellular endothelial delivery and interstitial lung macrophage expansion.

Expression profiling of osteopontin and its Argen Mamazhakypov 46 Basicreceptors in pressure overload-induced right ventricular remodeling in mice.

The BRD4 Inhibitor apabetalone (RVX-208) Eve Tremblay 63 BasicImproves experimental PaH in Sugen/hypoxia rat model.

Development of a 3-dimensional cell model Aida Llucia-Valldeperas 65 Basicto study right heart failure.

Epigenome-wide profiling uncovers novel gene Prakash Chelladurai 68 Basicregulatory networks in human pulmonary arterial hypertension.

Long non-coding RNa H19 a new signaling Junichi Omura 74 Basichub in the pathogenesis of right ventricular failure associated with pulmonary arterial hypertension.

FHL-1 is not involved in pressure overload Christine Veith 77 Basic-induced maladaptive right ventricular remodeling and dysfunction.

Reduced circulatory miR-34a levels and its Jianhui Lin 84 Basicrole in EndoMT in pulmonary arterial hypertension.

12 13


Increased protein O-GlcNacylation is Kurt Prins 97 Basicassociated with right ventricular dysfunction in pulmonary arterial hypertension.

Interleukin-6 as a potential modulator of right Kurt Prins 98 Basicventricular function via the microtubule-junctophilin-2-T-tubule pathway.

Multi-phase analysis of the right ventricular Baktybek Kojonazarov 103 Basicsystolic and diastolic function in rats with severe pulmonary hypertension using microCT.

Relationship of severity of pulmonary vascular Franz Rischard 107 Basicdisease to RV function across wsph groups:initial results from the pulmonary vascular

PhenOMICs Study (PVDOMOICS).

a novel histone deacetylase 6 inhibitor, C1a, Chien-Nien Chen 109 Basicattenuates pulmonary hypertension in rodent model.

Multi-beat right ventricular pulmonary arterial Rachel Damico 122 Basiccoupling predicts clinical worsening in PaH.

Compensated RV function in sugen-hypoxia Daniela Valdez-Jasso 127 Basicinduced PaH is largely driven by chamber stiffening.

association of RV stiffness with NTproBNP Olena Torbas 130 Basicdynamics during 6m treatment with sublingual sildenafil.

Beta receptor blockade fails to recover Jason Zelt 134 Basicventricular function despite increased pre-synaptic sympathetic nervous system function in experimental pulmonary arterial hypertension.

Mechanism for right ventricular hypertrophy Eduardo Macias 148 Basicassociated with pulmonary hypertension in Enriquezneonatal murine hypoxia.

Three-dimensional right ventricular regional Pei-Ni Jone 156 Basicstrain in paediatric pulmonary hypertension.



afterload and RV diastolic stiffness are Khodr Tello 157 Basicassociated with impaired ventilatory efficiency.

RNa expression profiles and regulatory Georg Hansmann 166 Basicnetworks in human right ventricular hypertrophy due to high pressure load.

Metabolic Signalling in PAHModerators: • Vinicio de Jesus Perez • Gopinath Sutendra


Targeting LOXL2 in pulmonary hypertension. Jochen Steppan 4 Basic

NRH: quinone Reductase 2 (NqO2), a new Rajamma Mathew 17 Basicplayer in pulmonary hypertension?

N-Lysine methyltransferase SMYD2-mediated Swathi Veeroju 26 Basicmethylation enhances HIF-1∂ stability and pro-angiogenic signalling.

Role of pyruvate kinase 2 muscle (PKM2) Nabham Rai 27 Basicoligomerization in pulmonary arterial hypertension.

Targeting aDORa1/PDE10a signalosome Chanil Valasarajan 29 Basicregulated caMP microenvironment as a novel therapeutic approach for pulmonary hypertension.

Heterogeneity in lung 18F-FDG uptake in Jeisson Osorio 31 Basicprecapillary pulmonary hypertension.

BOLa3 deficiency regulates mitochondrial Yi-Yin Tai 38 Basicand glycine metabolism in pulmonary hypertension.

RaSSF1a regulates HIF-1∂, triggering a feed Swati Dabral 42 Basicforward loop in hypoxia driven pulmonary hypertension.

Role of carbonic anhydrases in hypoxia and Aleksandar Petrovic 48 Basicnon-hypoxia induced pulmonary hypertension.

14 15


Decreased glycolysis as metabolic footprint of Valerie Smolders 49 Basicendothelial cells in chronic thromboembolic pulmonary hypertension.

Comparison of metabolic profile in endothelial Cristina Rodriguez 52 Basiccells of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension.

CLIC Proteins induce mitochondrial Mai Alzaydi 54 Basicidysfunctionn pulmonary arterial hypertension.

Pulmonary hypertension in children with Liu Xue Qin 56 Basicmethylmalonic acidemia: report of 30 cases.

Sustained hypoxic pulmonary vasoconstriction Ievgen Strielkov 81 Basicin mouse intrapulmonary arteries is dependent on epoxyeicosatrienoic acid pathway.

Role of MTH1 (NUTD1) in pulmonary arterial Roxane Paulin 120 Basichypertension (PaH): from oxidized nucleotides to survival.

Mitochondrial structure and function Kimberly 128 Basicrelationship in pulmonary hypertension: Dunham-Snaryelectron transport chain inhibition induces mitochondrial fragmentation and depolarization in vascular smooth muscle cells.

Endurance exercise training in pulmonary Gaurav Choudhary 129 Basichypertension is associated with alterations inelectron transport chain protein expression and supercomplex assembly.

NaDPH oxidase and autophagy in Himanshu Sharma 136 BasicHIV-1/opioids associated pulmonary arterial hypertension.


Latest on BMPR2, Signalling, Pathways, Genetic, Biomarkers & Mutations in PVDModerators: • Edda Frauke Spiekerkoetter • andrea Frump


FasL is a potential circulating biomarker during Djuro Kosanovi 5 Basicacute and chronic exposure to high altitude in Kyrgyz population.

Novel bone morphogenic protein receptor 2 Shine Kumar 24 Basicmutation in a patient with hereditary pulmonary

arterial hypertension.

Investigating the contribution of SOX17 Joy Shih 32 Basicmutations to the pathogenesis of pulmonary arterial hypertension.

RaP-011, a murine analog of sotatercept Sachindra Joshi 45 Basic(actRIIa-Fc), reverses pulmonary vascular remodelling, improves pulmonary haemodynamics, and restores right ventricular structure and function in a pre-clinical model of severe angio-obliterative pulmonary arterial Hypertension.

BMP9 phenotypically alters the lung Robert Szulcek 53 Basicmicrovascular endothelium of patients with pulmonary arterial hypertension.

BMPR2 mutant rat model unexpectedly Valerie Nadeau 62 Basicdevelops spontaneous breast tumor but no pulmonary hypertension.

The reduction of BMPR2 signalling Jun Yang 79 Basicpotentiates the development of pulmonary arterial hypertension in systemic lupus erythematosus.

Circulating proteomic biomarkers to screen for Peter Hickey 83 BasicPaH in systemic sclerosis.

Serum chloride is a prognostic marker in Kurt Prins 99 Basicpulmonary arterial hypertension.

Identification of novel genetic markers in other Carmen Perez 111 Basicforms of pulmonary hypertension. Olivares

16 17


Single cell analysis of lung endothelium Katharine Clapham 113 Basicidentifies distinct sub-populations: implications for genetics of pulmonary arterial hypertension.

Targeted exome sequencing in routine clinical Elena Dankovtseva 135 Basicpractice can help to elucidate pulmonary veno-occlusive disease in patients with pulmonary artery hypertension.

Disentangling the missing heritability of Stefan Gräf 139 Basicpulmonary arterial hypertension.

Translational analysis of RVT-1201 non-clinical Steve Wring 141 Basicand clinical pharmacokinetic and pharmacodynamic biomarker data to predict clinical dose of a novel tph inhibitor for treatment of pulmonary arterial hypertension.

Unique resting and exercise lipidomic profiles Scott Vasovatti 145 Basicof scleroderma-associated pulmonary arterial hypertension.

Inhibition of peptidyl-prolyl isomerase Pin1 Konda Babu Kurakula 147 Basicreverses vascular remodelling in pulmonary arterial hypertension via inhibition of TGF-ßsignalling.

Patterns of genetic and clinical adaptability to Samantha Sharma 159 Basicincreasing altitudes.

Genetic adaptation to high altitude. Qadar Pasha 160 Basic

Genotype and phenotype of Chinese children Hongsheng Zhang 164 Basicwith IPaH and HPaH.


Novel Signalling PathwaysModerators: • Harry Karmouty-quintana • Beata Wojciak-Stothard


Localization and nitrosylation of adenylyl cyclase Shyamala Dakshinamurti 44 Basicimpairs arterial relaxation in hypoxic PPHN.

CHK1 Elicits Therapeutic Effects in Olivier Boucherat 50 BasicPulmonary arterial Hypertension.

EZH2: a new factor involved in Pulmonary Olivier Boucherat 51 Basicarterial Hypertension?

The aSB2 E3 ubiquitin ligases as a novel target Li Gao 59 Basicfor scleroderma-associated pulmonary arterial hypertension.

The role of brain-derived neurotropic factor in Natascha Sommer 61 Basicpulmonary hypertension.

aDP induces human pulmonary artery smooth Nur Nabilah Abu Bakar 82 Basicmuscle cell migration in a P2Y12 dependant manner but P2Y12 inhibition has no therapeutic effect on monocrotaline-induced PaH in rats.

SPaRC is a novel contributor of PaSMC Ipek Vartürk Ozcan 85 Basicproliferation in pulmonary hypertension.

Inositol trisphosphate receptor-associated Siladitta Biswas 88 BasiccGMP-kinase substrate (IRaG) - deficient mice develop PKG1ß dependent pulmonary hypertension.

activation of Kv7 channels as a novel Angel Cogolludo 92 Basicmechanism for NO/cGMP-induced pulmonary vasodilation.

New insights into endothelial-to-mesenchymal Anastasia Gorelova 100 Basictransition in pulmonary hypertension: potential role for EBP50.

Pulmonary emphysema detected by microCT Baktybek Kojonazarov 102 Basicin rats with severe pulmonary hypertension induced by SU5416 and hypoxia.

18 19


Repeated embolization with blood clots Rozenn Quarck 104 Basiccontaining an inhibitor of angiogenesis induces chronic thromboembolic pulmonary hypertension in rabbits.

The role of FGF10 signalling in cigarette Stefan Hadzic 108 Basicsmoke-induced emphysema and pulmonary hypertension.

Characterizing the role of Rho/MRTF/SRF- Yajing Ji 121 Basicmediated gene transcription as a therapeutic target in pulmonary arterial hypertension.

The emerging role of Gas6/axl axis in pulmonary Tatyana Novoyatleva 123 Basicarterial hypertension.

Endothelial p300 is essential for pulmonary Hyung Chun 126 Basicvascular homeostasis and targets broad regulatory signaling networks in pulmonary arterial hypertension.

Therapeutic antibodies targeting human resistin Roger Johns 133 Basicprevents and reverses pulmonary arterial hypertension.

Secondary PHT & Systemic Disorders in PHTModerators: • Norbert Weissman • François Potus


Effects of HIV-1 and Schistosoma Daniel Morales Cano 43 Basicmansoni co-exposure on pulmonary vascular disease.

Pulmonary vascular disease associated with Jeff Fineman 55 Basiccongenital heart disease: comparison of ovine models to translate natural history into pathobiology.

Pulmonary arterial endothelial cells from Xue Manz 58 Basicchronic thromboembolic pulmonary hypertension patients show enhanced platelet adhesion.



Insulin-like growth factor-1 promotes Steven Abman 60 Basicangiogenesis, prevents pulmonary hypertension and preserves lung growth in experimental models of bronchopulmonary dysplasia.

Systemic circulation arteries structure and Yuriy Sirenko 96 Basicfunction in patients with idiopathic pulmonary arterial hypertension.

Balance between endothelium-pericyte injury Rafael Soares Godoy 101 Basicand repair determines pulmonary hypertensionin mouse model for targeted diphtheria toxin-induced cell death.

Peripheral digital vascular changes in Jordan Burgess 112 Basicpulmonary arterial hypertension.

Coronary artery remodeling a new component Sandra Martineau 114 Basicof right ventricular failure in PaH.

Sildenafil Inhibits pulmonary hypertension Milan Chovanec 115 Basicinduced by left heart pressure overload in rats.

Extracellular vesicles derived from hypoxic Laura Moreno Gutiérrez 142 Basicmesenchymal stem cells prevent pulmonary vascular dysfunction induced by lipopolysaccharide.

Pulmonary and systemic hypertension under Kavita Sharma 161 Basichypobaric hypoxia of high altitude.

END OF SESSION

20 21

Abstract poster presentations programme 2019

www.pvrinstitute.org


PVRI

22 23


PVRI

www.pvrinstitute.org

The PVRI is a Registered Charity in the UK, No: 1127115.

Documents

th PVRI Annual World Congress - pvrinstitute.org · pathway medications on hospitalization among patients with PH: a retrospective administrative claims study in a US managed care